In-depth Analysis and Forecast Of The Vasculitis Market On The Global As Well As Regional Level 2024
"The
Latest Research Report OpportunityAnalyzer: Vasculitis - Opportunity
Analysis and Forecast to 2024 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
About
Vasculitis Market
Vasculitis is a family of rare
autoimmune diseases, causing inflammation of the blood vessels,
arteries, veins or capillaries. The different forms of vasculitis are
classified by the size and location of the affected blood vessels .
This report specifically covers large vessel vasculitis (LLV),
Kawasaki disease (KD), antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis (AAV), and Behet's disease (BD). In
2014, there were 137,603 and 82,454 diagnosed prevalent and incident
cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan),
respectively. Untreated, the organs and tissues affected by the
damaged blood vessels do not get enough blood, which can lead to
organ or tissue damage, or even death. J&J's Remicade was the
first biologic in the vasculitis market, approved for BD in Japan in
2007. Other biologics approved for vasculitis include AbbVie's Humira
for BD in Japan and Biogen/Roche's Rituxan for GPA/MPA in the 7MM.
Several unmet needs still remain such as the development of drugs
with improved safety and efficacy for use in both the induction and
maintenance treatment settings . GlobalData expects the launch of six
drugs during the 2014 to 2024 forecast period along with increased
diagnosed patient numbers will drive the vasculitis market.
Highlights
Key Questions Answered
- How large an impact will
biosimilars have on the vasculitis market? What do vasculitis
specialists and key opinion leaders across the 7MM think about the
evolving treatment landscape?
- What opportunities remain in the
market for new product entrants?
- With six drug launches, five of
which are biologics, which products are forecast to generate the
highest sales over 2014-2024? How are product launches expected to
affect the sales of induction and maintenance therapies?
- According to KOLs, what are the
most important unmet needs in vasculitis? Will these needs be
addressed by pipeline agents? What needs will remain by the end of
the forecast period in 2024?
- What industry developments are
likely to affect sales of the top-selling vasculitis drugs in the
markets researched? Which is the largest growth market globally?
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/699484
Key Findings
- Biosimilars are expected to
change the landscape for vasculitis and create pricing pressure in
the vasculitis market. However, questions from physicians and
regulators regarding the appropriate use of biosimilars still
lingers.
- Sales of immunosuppressants are
expected to decline due to the introduction of novel biologics and
small molecules to treat vasculitis.
- Several unmet needs are expected
to remain after the forecast period, as all pipeline drugs are in
development as induction therapies and maintenance therapies are
lagging.
- With several major
pharmaceutical companies involved in development of vasculitis
products, the market will be dominated by Big Pharma who will
leverage their R&D, manufacturing, and distribution networks.
Scope
- Overview of vasculitis,
including etiology, pathophysiology, and country-specific diagnosis
and treatment recommendations.
- Annualized vasculitis market
revenue, annual cost of therapy and treatment usage pattern data from
2014 and forecast for ten years to 2024.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, and implications for the vasculitis market.
- Pipeline analysis: comprehensive
data split across different phases and emerging trends, specifically
BMSs Orencia, GSKs Benlysta and Nucala, Genentech/Roches Actemra,
Celgenes Otezla, J&Js Remicade, and biosimilars (such as
Celltrion/Hospira/Alvogens Inflectra/Remsima).
- Analysis of the current and
future market competition in the global vasculitis market. Insightful
review of the key industry and governmental drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the vasculitis market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global vasculitis market
in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the global
vasculitis market from 2014-2024.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/699484
Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 19
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 21
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Types of Vasculitis 22
3.2 Etiology and Pathophysiology
23
3.2.1 Large Vessel Vasculitis 23
3.2.2 Kawasaki Disease 24
3.2.3 ANCA-Associated Small Vessel
Vasculitis 25
3.2.4 Behets Disease 26
3.3 Symptoms 26
3.4 Disease Management 27
3.4.1 Classification Criteria 27
3.4.2 Disease Management
Guidelines 28
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and Comorbidities
35
4.3 Global Trends 36
4.4 Forecast Methodology 39
4.4.1 Sources Used 41
4.4.2 Sources Not Used 61
4.4.3 Forecast Assumptions and
Methods 61
4.5 Epidemiological Forecast for
Vasculitis, 2014-2024 85
4.5.1 Diagnosed Incident Cases of
AAV 85
4.5.2 Diagnosed Prevalent Cases of
AAV 87
4.5.3 Age-Standardized Incidence
of AAV 89
4.5.4 Diagnosed Incident Cases of
LVV - TA and GCA 92
4.5.5 Diagnosed Prevalent Cases of
TA 94
4.5.6 Age-Standardized Incidence
of LVV 96
4.5.7 Diagnosed Incident Cases of
BD 98
4.5.8 Diagnosed Prevalent Cases of
BD 100
4.5.9 Age-Standardized Incidence
of BD 102
4.5.10 Diagnosed Incident Cases of
KD 103
4.6 Discussion 105
4.6.1 Epidemiological Forecast
Insight 105
4.6.2 Limitations of the Analysis
106
4.6.3 Strengths of the Analysis
107
5 Current Treatment Options 109
5.1 Overview 109
5.2 Product Profiles 111
5.2.1 Rituxan (Rituximab) 111
5.2.2 Humira (Adalimumab) 115
5.2.3 Remicade (Infliximab) 120
5.2.4 Mycophenolate Mofetil 125
5.2.5 Cyclophosphamide 129
5.2.6 Azathioprine 133
5.2.7 Methotrexate 137
5.2.8 Glucocorticoids 140
5.2.9 Intravenous Immunoglobulin
143
6 Unmet Needs Assessment and
Opportunity Analysis 147
6.1 Overview 147
6.2 Improved Drug Efficacy and
Safety in the Induction Therapy Setting 148
6.2.1 Unmet Need 148
6.2.2 Gap Analysis 149
6.2.3 Opportunity 151
6.3 Improved Drug Efficacy and
Safety in the Maintenance Therapy Setting 151
6.3.1 Unmet Need 151
6.3.2 Gap Analysis 152
6.3.3 Opportunity 153
6.4 Biomarkers to Predict
Responsiveness to Therapy 154
6.4.1 Unmet Need 154
6.4.2 Gap Analysis 154
6.4.3 Opportunity 154
6.5 Biomarkers to Predict Disease
Relapse 155
6.5.1 Unmet Need 155
6.5.2 Gap Analysis 155
6.5.3 Opportunity 156
6.6 Early and Non-invasive
Diagnosis of Vasculitis 156
6.6.1 Unmet Need 156
6.6.2 Gap Analysis 157
6.6.3 Opportunity 158
6.7 Adjunctive Therapy for the
Treatment of KD 158
6.7.1 Unmet Need 158
6.7.2 Gap Analysis 160
6.7.3 Opportunity 161
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment